Clinical trials: Myeloma, Plasma-Cell
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S.
- Trial name
- NCT02368301
- Testing
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Sponsor
- Bristol-Myers Squibb
Newly Diagnosed Multiple Myeloma
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
This is a Phase III open-label, 3-arm, parallel, randomized, controlled trial. The allocation ratio 1:1:1 and outcome assessment are blind to group allocation. Patients will be randomized from 3 arms.
- Trial name
- GEM21menos65 (NCT05558319)
- Testing
- Bortezomib, Isatuximab, Iberdomide
- Where
- 68 sites in Spain
- Volunteers
- 480 people
- Sponsor
- PETHEMA Foundation
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloma, Lymphoma
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
A prospective study in which hematological oncology patients who were vaccinated against RSV will undergo a blood test to assess their immune response to the vaccine.
- Conditions
- Myeloma, Lymphoma, CLL, Myelodysplastic Syndrome
- Trial name
- NCT06944119
- Where
- Israel
- Volunteers
- 250 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Multiple Myeloma
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
- Trial name
- NCT06228794
- Testing
- Peripheral blood test
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a…
- Trial name
- NCT04786028
- Testing
- Isatuximab
- Where
- 7 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Canadian Myeloma Research Group
Relapsed/Refractory Multiple Myeloma
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma
- Trial name
- NCT05980507
- Testing
- ICI201
- Where
- China
- Sponsor
- The First Affiliated Hospital of Soochow University
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Multiple Myeloma
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
- Trial name
- NCT06105554
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.
- Trial name
- BelaRd (NCT04808037)
- Testing
- Belantamab mafodotin
- Where
- Greece
- Volunteers
- 66 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma, Caregiver Subjective Burden
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL.
- Conditions
- Multiple Myeloma, Caregiver Subjective Burden, Quality of Life (QOL)
- Trial name
- NCT06610045
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- PeriPharm
Multiple Myeloma
MInimal Residual Disease Adapted Strategy
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates.
- Trial name
- MIDAS (NCT04934475)
- Testing
- Isatuximab, ASCT
- Where
- 73 sites in Belgium, France and 1 more
- Volunteers
- 791 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
- Trial name
- NCT06997081
- Testing
- Lenalidomide, Dexamethasone, Elranatamab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Miami
Relapsed Refractory Multiple Myeloma (RRMM)
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or…
- Trial name
- NCT07455851
- Testing
- Linvoseltamab, REGN17372+Linvoseltamab
- Where
- 8 sites in Australia, Greece
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Smoldering Multiple Myeloma
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical…
- Trial name
- NCT05597345
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Trial name
- NCT04566328
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 647 sites in United States, Puerto Rico
- Volunteers
- 1,450 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myeloma
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02902965
- Testing
- Ibrutinib, Bortezomib, Dexamethasone
- Where
- 33 sites in Czechia, Germany and 4 more
- Volunteers
- 74 people
- Sponsor
- Pharmacyclics Switzerland GmbH
Multiple Myeloma, Multiple Myeloma in Relapse
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
This is a phase I/II study of perifosine in combination with bortezomib-with or without dexamethasone-for patients with relapsed or refractory multiple myeloma previously treated with bortezomib.
- Trial name
- NCT00401011
- Testing
- Perifosine, Bortezomib, Dexamethasone
- Volunteers
- 84 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
RATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma.
- Trial name
- NCT00942422
- Testing
- defined green tea catechin extract, gene expression analysis, protein analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.